Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Sectoral Asset Management

Investor type Private Equity Firm
Founders Franklin Berger Jerome Pfund Michael Sjostrom


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 45
Average round size
The average size of a deal this fund participated in
Portfolio companies 31
Rounds per year 1.96
Lead investments 5
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 14
Key employees 5
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Therapeutics
  • Pharmaceutical

Sectoral Asset Management appeared to be the Corporate Investor, which was created in 2000. The leading representative office of defined Corporate Investor is situated in the Montru00e9al. The venture was found in North America in Canada.

The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the Sectoral Asset Management, startups are often financed by HealthCap, Astellas Venture Management, Ysios Capital. The meaningful sponsors for the fund in investment in the same round are Ysios Capital, Andera Partners, Versant Ventures. In the next rounds fund is usually obtained by T. Rowe Price, Ysios Capital, Venrock.

Among the most popular portfolio startups of the fund, we may highlight F2G, BioVex, HighLife. The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular fund investment industries, there are Personal Health, Medical Device.

This organization was formed by Franklin Berger, Jerome Pfund, Michael Sjostrom. The overall number of key employees were 4.

The usual things for fund are deals in the range of 10 - 50 millions dollars. Opposing the other organizations, this Sectoral Asset Management works on 12 percentage points more the average amount of lead investments. The fund is constantly included in 2-6 investment rounds annually. The top activity for fund was in 2015. The real fund results show that this Corporate Investor is 6 percentage points less often commits exit comparing to other companies. The higher amount of exits for fund were in 2019.

Read more

Funds with similar focus

Funds from Canada
Funds with similar focus located in Canada:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Amador Holdings Ciudad De Panamá, Panamá, Panama
B5 Capital -
Cameleon Invest France, Ile-de-France, Paris
Carnegie Technologies San Antonio, Texas, United States
China Health Industry Investment Fund -
Crescent Point Energy Alberta, Calgary, Canada
Cure Kids Ventures -
Fupeng Asset China, Guangdong, Shenzhen
Health for Life Capital fund -
Hebei Jijin China, Hebei, Hebei
Huihua Investment China, Fenghua, Zhejiang
InReach Ventures England, London, United Kingdom
Jinan Tongtai China, Jinan, Shandong
Merrill Lynch Canada Inc Canada, Ontario, Toronto
MiMo Capital Florida, Miami, United States
Pacific 6 Enterprises California, Long Beach, United States
The Sapir Organization New York, New York, United States
Westscheme Pty Limited Australia, Perth, Western Australia
Xingfen Yaotu China, Zhejiang, Zhoushan
Yifan Capital -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Amolyt Pharma

Health Care
$153M06 Jan 2023 Écully, Rhone-Alpes, France


Health Care
Medical Device
$79M23 Dec 2022 Cambridge, Massachusetts, United States


Health Care
$23M30 Aug 2022 White Plains, New York, United States

Mineralys Therapeutics

$118M08 Jun 2022 Radnor, Pennsylvania, United States


Health Care
Medical Device
$62M04 May 2022 Cambridge, Massachusetts, United States

Magnolia Medical Technologies

Health Care
Health Diagnostics
Medical Device
$46M16 Feb 2022 Seattle, Washington, United States


$43M03 Nov 2021 Boston, Massachusetts, United States

Better Therapeutics

Artificial Intelligence
Health Care
Information Technology
$70M29 Oct 2021 San Francisco, California, United States

Babylon Health

Artificial Intelligence
Health Care
Health Diagnostics
Mobile Apps
$230M22 Oct 2021 London, England, United Kingdom
Garuda Therapeutics Raises $72M in Series A Financing

– Garuda Therapeutics from Cambridge develops off-the-shelf, durable blood stem cell therapies.
– Series A funding of $72m brings company valuation to more than $1b.
– The round was led by Aisling Capital, Northpond Ventures and Orbimed, supported by Cormorant Asset Management, Ridgeback Capital Investments, Monashee Investment Management, Sectoral Asset Management, National Resilience, Inc. (Resilience), Mass General Brigham Ventures, among others.

Amolyt Pharma Raises $80M in Series B Financing

– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Sectoral Asset Management?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: